Skip to main content
SpringerLink
Log in

Cognitive effects of l-deprenyl in Alzheimer's disease

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Monoamine neurotransmitter systems, along with cholinergic systems, are known to play important roles in cognition, and are disrupted in at least some patients with dementia of the Alzheimer type (DAT). This suggests that monoamine-enhancing drugs might ameliorate cognitive symptoms in certain patients with DAT. l-Deprenyl is a monoamine oxidase (MAO) inhibitor which may selectively inhibit MAO-B at low doses, while at high doses it nonselectively inhibits MAO-A as well as MAO-B. We studied its effects on several types of cognitive function in 17 patients with DAT. Two doses of l-deprenyl (10 mg/day and 40 mg/day) and placebo were compared in a double-blind, serial treatment design. Episodic learning and memory, knowledge memory, attention, recognition, and performance on a continuous performance task were assessed at baseline and under these drug and placebo conditions. Statistically significant improvement was noted in performance on an episodic memory and learning task requiring complex information processing and sustained conscious effort during treatment with l-deprenyl 10 mg/day. Knowledge memory, intrusions, and other cognitive functions relevant to DAT were not altered by l-deprenyl at either dose.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adolfsson R, Gottfries CG, Roos BE, Winblad B (1979) Changes in brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 135:216–223

    Google Scholar 

  • Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B (1980) Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. Life Sci 17:1029–1034

    Google Scholar 

  • Anzelark GM, Crow TJ, Greenway AP (1973) Impaired learning and decreased cortical norepinephrine after bilateral locus coeruleus lesions. Science 181:682–684

    Google Scholar 

  • Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43(2):388–393

    Google Scholar 

  • Birkmayer W, Riederer P, Youdim MBH (1982) (-) Deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol 5(2):195–230

    Google Scholar 

  • Bondareff W, Mountjoy CQ, Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Neurology 32:164–168

    Google Scholar 

  • Brinkman S, Gershon S (1983) Measurement of cholinergic drug effect on memory in Alzheimer's disease. Neurobiol Aging 4:139–145

    Google Scholar 

  • Buschke H (1973) Selective reminding for the analysis of memory and learning. J Verb Learn Verb Behav 12:543–550

    Google Scholar 

  • Clark ANG, Mankikar GD (1979) d-Amphetamine in elderly patients refractory to rehabilitation procedures. J Am Geriatr Soc 27:174–177

    Google Scholar 

  • Cohen RM, Weingartner H, Smallberg SA, Pickar D, Murphy DL (1982) Effort and cognition in depression. Arch Gen Psychiatry 32:593–597

    Google Scholar 

  • Cohen RM, Cohen MR, Weingartner H, Pickar D, Murphy DL (1983) Naloxone affects task performance in normal subjects. Psychiatry Res 8:127–136

    Google Scholar 

  • Cohen RM, Sunderland T, Aulakh CS (1984) Antidepressants in states of cognitive dysfunction. Drug Dev Res 4:517–532

    Google Scholar 

  • Crook T, Ferris S, Sathananthan G, Raskin A, Gershon S (1977) The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacology 52:251–257

    Google Scholar 

  • Cross AJ, Crow TJ, Perry EK, Perry RH, Blessed G, Tomlinson BE (1981) Reduced dopamine-beta-hydroxylase activity in Alzheimer's disease. Br Med J 282:93–94

    Google Scholar 

  • Elliott PB (1964) Tables of d1. In: Swets JA (ed) Signal detection and recognition by human observers. Wiley, New York, pp 651–684

    Google Scholar 

  • Ellsworth JD, Glover V, Reynolds GP, Sandler M, Lees AJ, Phuapradit P, Shaw KM, Stein GM, Kumar P (1978) Deprenyl administration in man: A selective monoamine oxidase inhibitor without the “cheese” effect. Psychopharmacology 57:33–38

    Google Scholar 

  • Francis PT, Palmer AM, Sims NR, Bowen DM, Davison AN, Esiri MM, Neary D, Snowdon JS, Wilcock GK (1985) Neurochemical studies of early-onset Alzheimer's disease: Possible influence on treatment. N Engl J Med 313(1):7–11

    Google Scholar 

  • Fuld PA, Katzman R, Davies P, Terry RD (1982) Intrusions as a sign of Alzheimer dementia: Chemical and pathological verification. Ann Neurol 11:155–159

    Google Scholar 

  • Glass RM, Uhlenhuth EH, Hartel FW, Matuzas W, Fischman MW (1981) Cognitive dysfunction and imipramine in outpatient depressives. Arch Gen Psychiatry 38:1048–1051

    Google Scholar 

  • Gorelick DA, Bozewicz TR, Bridger WH (1975) The role of catecholamines in animal learning and memory. In: Friedhoff AJ (ed) Catecholamines and behavior, vol 2. Plenum, New York, pp 1–30

    Google Scholar 

  • Gottfries CG (1985) Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 86:245–252

    Google Scholar 

  • Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Psychol 6:278–296

    Google Scholar 

  • Hasher L, Zacks RJ (1979) Automatic and effortful processes in memory. J Exp Psychol [Gen] 108:386–388

    Google Scholar 

  • Henry GM, Weingartner H, Murphy DL (1973) The influence of affective states and psychoactive drugs on verbal learning and memory. Am J Psychiatry 130:966–971

    Google Scholar 

  • Hopkins NF, Johnston D (1984) Frequency-dependent noradrenergic modulation of long-term potentiation in the hippocampus. Science 226:350–352

    Google Scholar 

  • Karoum F, Chuang L-W, Eisler T, Calne DB, Liebowitz MR, Quitkin MR, Klein DF, Wyatt RJ (1982) Metabolism of (-) deprenyl to amphetamine and methamphetamine. Neurology 32:503–509

    Google Scholar 

  • Kety SF (1970) The biogenic amines in the central nervous system: Their possible roles in arousal, emotion, and learning. In: Schmitt FO (ed) The neurosciences: second study program. Rockefeller Press, New York, pp 324–336

    Google Scholar 

  • Knoll J (1976) Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. CIBA Foundation Symposium 39, Monoamine oxidase and its inhibition. Elsevier/North Holland, Excerpta Medical, pp 135–161

  • Knoll J, Ecseri Z, Kelmen K, Nievel J, Knoll B (1965) Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Arch Int Pharmacodyn Ther 155(1):154–164

    Google Scholar 

  • Mann DA, Lincoln J, Yates PO, Stamp JE, Toper S (1980) Changes in the monoamine containing neurons of the human CNS in senile dementia. Br J Psychiatry 136:533–541

    Google Scholar 

  • Mann JJ, Frances A, Kaplan R, Kocsis J, Peselow ED, Gershon S (1982) The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. J Clin Psychopharmacol 2:54–57

    Google Scholar 

  • McGaugh JL (1983) Hormonal influences on memory. Annu Rev Psychol 34:297–323

    Google Scholar 

  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology 34:939–944

    CAS  PubMed  Google Scholar 

  • Mendis N, Pare CMB, Sandler M, Glover V, Stern GM (1981) Is the failure of (-) deprenyl, a selective MAO B inhibitor, to alleviate depression related to freedom from cheese effect? Psychopharmacology 73:87–90

    Google Scholar 

  • Mendlewicz J, Youdim MBH (1983) l-Deprenil, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double-blind evaluation. Br J Psychiatry 142:508–511

    Google Scholar 

  • Moss MB, Albert MS, Butters N, Payne M (1986) Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease, and alcoholic Korsakoff's syndrome. Arch Neurol 43:239–246

    Google Scholar 

  • Murphy DL, Henry GM, Weingartner H (1972) Catecholamines and memory: Enhanced verbal learning during l-dopa administration. Psychopharmacologia 27:319–326

    Google Scholar 

  • Palermo DS, Jenkins JJ (1964) Word association norms: Grade school through college. Univ Minnesota Press, Minneapolis

    Google Scholar 

  • Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO (1984) l-Deprenyl in atypical depressives. Arch Gen Psychiatry 41:777–781

    Google Scholar 

  • Reisberg B, Ferris SH, DeLeon MJ, Crook T (1982) The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 139(9):1136–1139

    Google Scholar 

  • Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM (1978) Deprenyl is metabolized to amphetamine and methamphetamine in man. Br J Clin Pharmacol 6:542–543

    CAS  PubMed  Google Scholar 

  • Reus VI, Silberman E, Post RM, et al. (1979) d-Amphetamine: Effects on memory in a depressed population. Biol Psychiatry 14:345–356

    Google Scholar 

  • Robinson DS, Davis JM, Nies A, Colburn RW, Davis JN, Bourne HR, Bunney WE, Shaw DM, Coppen AJ (1972) Ageing, monoamines, and monoamine oxidase levels. Lancet I:290–291

    Google Scholar 

  • Rossor MN, Iversen LL, Reynolds GP, Mountjoy CO, Roth M (1984) Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 288:961–964

    Google Scholar 

  • Rosvold HE, Mirsky AF, Sarason I (1956) A continuous performance test of brain damage. J Consult Clin Psychol 20:343–350

    Google Scholar 

  • Roy-Byrne PP, Weingartner H, Bierer L, Thompson K, Post RM (1986) Effortful and automatic cognitive processes in depression. Arch Gen Psychiatry 43:265–267

    Google Scholar 

  • Squire LR, Davis HP (1981) The pharmacology of memory: A neurobiological perspective. Annu Rev Pharmacol Toxicol 21:323–356

    Google Scholar 

  • Sternberg DE, Jarvik ME (1976) Memory functions in depression: Improvement with antidepressant medication. Arch Gen Psychiatry 33:219–224

    Google Scholar 

  • Sunderland T, Tariot PN, Cohen RM, Weingartner H, Mueller EA, Murphy DL (1987) Anticholinergic sensitivity in Alzheimer patients and age-matched controls. Arch Gen Psychiatry (in press)

  • Tariot PN, Sunderland T, Weingartner H, Murphy DL, Cohen MR, Cohen RM (1986) Naloxone and Alzheimer's disease. Arch Gen Psychiatry 43:727–732

    Google Scholar 

  • Tariot PN, Weingartner H (1986) A psychobiologic analysis of cognitive failures: Structure and mechanisms. Arch Gen Psychiatry 43:1183–1188

    Google Scholar 

  • Tariot PN, Cohen RM, Sunderland T, Newhouse PA, Yount D, Mellow AM, Weingartner H, Mueller EA, Murphy DL (1987) l-deprenyl in Alzheimer's disease: preliminary evidence for behavioral change with MAO-B inhibition. Arch Gen Psychiatry (in press)

  • Weingartner H, Cohen RM, Murphy DL, Martello J, Gerdt C (1981) Cognitive processes in depression. Arch Gen Psychiatry 38:42–47

    Google Scholar 

  • Weingartner H, Grafman J, Boutelle W, Kaye W, Martin PR (1983) Forms of memory failure. Science 221:380–382

    Google Scholar 

  • Wise RA (1978) Catecholamine theories of reward: A critical review. Brain Res 152:215–247

    Google Scholar 

  • Woods SW, Tesar GE, Murray GB, Cassem NH (1986) Psychostimulant treatment of depressive disorders secondary to medical illness. J Clin Psychiatry 47:12–15

    Google Scholar 

  • Yates CM, Simpson J, Gordon A, Maloney AFJ, Allison Y, Ritchie IM, Urquhart A (1983) Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280:119–126

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Clinical Science, National Institute of Mental Health, 20892, Bethesda, MD, USA

    P. N. Tariot, T. Sunderland, D. L. Murphy, J. A. Welkowitz & K. Thompson

  2. Psychiatry Unit, Monroe Community Hospital, University of Rochester, School of Medicine, 435 East Henrietta Road, 14603, Rochester, NY, USA

    P. N. Tariot

  3. Psychology Department, The George Washington University, 20052, Washington, DC, USA

    H. Weingartner

  4. Laboratory of Cerebral Metabolism, National Institute of Mental Health, 20892, Bethesda, MD, USA

    R. M. Cohen

Authors
  1. P. N. Tariot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Sunderland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Weingartner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. L. Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. A. Welkowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. M. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tariot, P.N., Sunderland, T., Weingartner, H. et al. Cognitive effects of l-deprenyl in Alzheimer's disease. Psychopharmacology 91, 489–495 (1987). https://doi.org/10.1007/BF00216016

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216016

Key words

Search

Navigation